Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preseasonal rush Depigoid Grass Mix as add-on therapy in grass pollen–sensitized allergic rhinitis/rhinoconjunctivitis
2006-003065-14Phase 3Completed
- Sponsor
- LETI Pharma
- Start
- Nov 2006
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of Depigoid Grass Mix in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and asthma, sponsored by LETI Pharma. Primary endpoints: Efficacy of preseasonal rush Depigoid Grass Mix add-on therapy and Safety of preseasonal rush Depigoid Grass Mix add-on therapy. Started Nov 2006; status: completed.
02
Drugs
Depigoid Grass Mix
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2006-003065-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003065-14.